Company Tekmira Pharmaceuticals Corporation Toronto S.E.
Equities
TKM
CA87911B2093
Pharmaceuticals
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Therapeutics
100.0
%
| 39 | 100.0 % | 18 | 100.0 % | -53.51% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 39 | 100.0 % | 18 | 100.0 % | -53.51% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 50 | 01/14/01 | |
David Hastings
DFI | Director of Finance/CFO | 62 | 11/18/11 |
Karen Sims
CTO | Chief Tech/Sci/R&D Officer | 53 | 01/17/01 |
Michael Sofia
CTO | Chief Tech/Sci/R&D Officer | 66 | 01/15/01 |
John Naftzger
CMP | Compliance Officer | 57 | 10/23/10 |
Investor Relations Contact | - | 21/21/21 | |
Shannon Briscoe
HRO | Human Resources Officer | - | 01/21/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 68 | 01/14/01 | |
James Meyers
BRD | Director/Board Member | 59 | 23/18/23 |
Daniel Burgess
BRD | Director/Board Member | 62 | 23/17/23 |
Keith Manchester
BRD | Director/Board Member | 55 | 04/15/04 |
Frank Torti
CHM | Chairman | 45 | 26/18/26 |
Chief Executive Officer | 50 | 01/14/01 | |
Director/Board Member | 54 | 12/23/12 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 188,717,409 | 146,657,129 ( 77.71 %) | 0 | 77.71 % |
Company contact information
![address Tekmira Pharmaceuticals Corporation(TKM)](https://cdn.zonebourse.com/static/address/1411938.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+2.08% | 95.18B | |
-4.34% | 37.55B | |
+76.24% | 28.2B | |
-14.61% | 15.63B | |
-3.46% | 13.63B | |
-12.31% | 11.5B | |
+184.77% | 10.81B | |
-54.13% | 9.23B | |
+5.54% | 9.09B |